Basic Metformin + Glyburide Information

• INN (International Nonproprietary Name): Metformin and Glyburide.
• Brand Names Available In United Kingdom: Glucovance (original brand), with generics dominating; typical pack types include blisters of 30 or 60 tablets in EU markets and the original Glucovance listed in some countries.
• ATC Code: A10BD03 (A10: Drugs used in diabetes; A10B: Blood glucose lowering drugs, excl. insulins; A10BD: Combinations of oral blood glucose lowering drugs).
• Forms & Dosages: Oral tablets combining glyburide/metformin in strengths 1.25mg/250mg, 2.5mg/500mg and 5mg/500mg.
• Manufacturers In United Kingdom: Not specified; global manufacturers include Teva, Apotex, Aurobindo and Sandoz for US/EU generics, with Indian suppliers such as USV and Micro Labs.
• Registration Status In United Kingdom: Not specified; generics authorised in the EU/EMA and Glucovance approved by FDA in the USA per the product information.
• OTC / Rx Classification: Prescription only (Rx) globally.
• Standard Dosages By Condition: For adults with Type 2 diabetes start 1.25mg/250mg once or twice daily with meals; titrate every two weeks up to a maximum of 20mg glyburide/2000mg metformin per day. Not for Type 1 diabetes or paediatric use.

Latest Research Highlights (UK & EU, 2022–2025)

Patients and clinicians often ask whether the metformin + glyburide combination still has a role given newer agents and recent audits.

Recent UK and EU practice audits and registry reports have reinforced the pharmacological rationale for combining metformin with a sulfonylurea such as glyburide: metformin targets insulin resistance while glyburide enhances insulin secretion.

NHS primary‑care audits and European diabetes registries note consistent HbA1c reductions when adding a sulfonylurea to metformin versus metformin monotherapy, particularly for people with moderate hyperglycaemia who need intensification of oral therapy.

Safety remains the trade‑off, with observational datasets showing higher hypoglycaemia incidence compared with metformin alone, a signal especially notable in older patients.

Regulatory vigilance from MHRA Yellow Card trends and EU monitoring has logged reports of hypoglycaemia and occasional hepatic or renal cautions rather than new class‑wide toxicities.

Comparative effectiveness versus newer combinations such as metformin plus an SGLT2 or DPP‑4 inhibitor suggests similar short‑term glycaemic control but less robust evidence for cardiovascular and renal benefits with metformin+glyburide.

Practical data points to the fixed‑dose options (1.25/250mg to 5/500mg) and the licensed maximum of 20mg/2000mg per day as the standard dosing envelope used in audits and formularies.

Top Efficacy Findings: consistent HbA1c reduction when escalated from metformin monotherapy; good fasting and post‑prandial control in dual‑therapy candidates; useful adherence benefit from single‑tablet formulations.

Top Safety Signals: increased hypoglycaemia (elderly at higher risk); GI effects attributable to metformin; vigilance for lactic acidosis risk in renal impairment.

Clinical Effectiveness In The UK (Nhs Outcomes & Patient Reports)

Many patients wonder how well the metformin + glyburide combination performs in everyday NHS practice.

Within NHS primary care, fixed‑dose metformin+glyburide tablets are used for adults with Type 2 diabetes who need intensification but are not yet on insulin.

Local audits indicate meaningful HbA1c improvements after escalation from metformin monotherapy, with many patients reporting better fasting and post‑prandial glucose control.

Patient reports commonly describe episodic hypoglycaemia symptoms such as dizziness, sweating and shakiness, especially when meals are missed or alcohol is consumed.

Gastrointestinal adverse effects typical of metformin—nausea and diarrhoea—are often mentioned as adherence barriers when doses are increased too quickly.

UK clinical guidance in many trusts emphasises individualised therapy and tends to favour alternatives such as gliclazide or metformin plus DPP‑4/SGLT2 agents for older people or those at high hypoglycaemia risk.

Standard NHS outcome measures stress annual review with eGFR monitoring, HbA1c, weight and blood pressure, and clear safety counselling on hypoglycaemia.

Contraindications commonly cited in practice notes include eGFR <30 ml/min, Type 1 diabetes and risk factors for lactic acidosis.

• NHS Outcome Metrics (typical): baseline HbA1c, mean reduction after treatment escalation, hypoglycaemia episode counts, renal function threshold monitoring.
• Patient Self‑Care Tips: carry fast‑acting carbohydrate, check blood glucose when unwell, report recurrent lows to GP or pharmacist.

Indications & Expanded Uses (Mhra‑Approved Vs Off‑Label)

People often ask what this combination is officially for and when clinicians might use it off‑label.

MHRA‑aligned product information frames metformin+glyburide for adults with Type 2 diabetes who require dual oral therapy where separate agents are appropriate.

The fixed‑dose combination simplifies regimens and is typically started at 1.25mg/250mg once or twice daily with meals and titrated every two weeks within the licensed maximum of 20mg glyburide/2000mg metformin daily.

Off‑label use can occur in clinician‑led scenarios such as temporary bridging before insulin initiation or selective use when patients are intolerant of other sulfonylureas, provided a documented rationale exists.

Use is explicitly not recommended in Type 1 diabetes, pregnancy, lactation or in children pending safety data.

For hepatic impairment and patients with recurrent lactic acidosis risk the guidance is to avoid the combination or to seek specialist advice.

• Approved Indication: Type 2 diabetes mellitus in adults requiring combined oral therapy.
• Common Off‑Label Scenarios: short‑term bridge to insulin, selective substitution when other sulfonylureas are not tolerated.
• Explicit Contraindications: eGFR <30 ml/min, Type 1 diabetes, pregnancy, lactation, known hypersensitivity.

Clinicians must confirm renal function prior to initiation and record shared decision‑making in the medical record.

Composition & Brand Landscape (UK Market Focus)

Patients often ask what is actually in these tablets and which brands they might see in pharmacies.

The tablets combine metformin, a biguanide, with glyburide (glibenclamide), a second‑generation sulfonylurea, in fixed doses.

Common strengths internationally are 1.25mg/250mg, 2.5mg/500mg and 5mg/500mg, all as oral tablets.

The original branded preparation Glucovance has largely been replaced by generics in many markets, and the UK supply is now dominated by generics from manufacturers such as Teva, Apotex, Aurobindo and Sandoz according to product listings.

Packaging is typically blister packs of 30 or 60 tablets in EU supply chains, with local NHS dispensing of generics or branded generics depending on the formulary.

Pharmacies such as Boots and LloydsPharmacy, plus NHS‑affiliated online suppliers, commonly stock generics; pricing and whether a patient pays depends on local prescription charge rules.

Contraindications & Special Precautions (High‑Risk Groups)

Patients worry who should not take the combination and who needs closer monitoring.

Absolute contraindications include severe renal impairment (eGFR <30 ml/min), metabolic acidosis or diabetic ketoacidosis, known hypersensitivity to either component and Type 1 diabetes.

Elderly patients require special caution because of greater susceptibility to hypoglycaemia and lactic acidosis, so start at the lowest dose and monitor renal function regularly.

Hepatic impairment, recent major surgery or trauma, excessive alcohol use and adrenal or pituitary insufficiency are conditions where use is discouraged or requires close supervision.

Driving and safety at work require clear counselling about hypoglycaemia risk and the need to avoid driving if unwell or after a hypoglycaemic episode.

Pregnancy and breastfeeding are not recommended contexts for this combination; specialist referral is advised.

Monitoring Checklist: baseline eGFR, liver function tests, HbA1c, full medication reconciliation for interactions, and patient education on hypoglycaemia recognition and emergency carbohydrates.

Advise patients on missed‑dose guidance: take as soon as remembered unless close to the next dose and do not double doses.

Report suspected new adverse reactions to the MHRA Yellow Card scheme.

Dosage Guidelines (Nhs‑Aligned Regimens And Adjustments)

People commonly ask how to start and adjust doses safely within NHS practice.

Typical NHS initiation is 1.25mg/250mg once or twice daily with meals with dose titration every two weeks according to glycaemic response and tolerability.

The maximum recommended total daily dose is 20mg glyburide/2000mg metformin.

Elderly patients should begin at the lowest available dose and have more frequent renal checks during titration.

Renal impairment is a key determinant: the combination is contraindicated if eGFR <30 ml/min and specialist advice is advised for eGFR 30–45 ml/min.

Hepatic impairment is another reason to avoid the combination or to consult a specialist.

Perioperative management and contrast studies require temporary suspension of metformin where there is risk of renal function decline; follow local NHS trust guidance for timing of interruption and restart.

• Initiation: 1.25mg/250mg once daily with food.
• Titration: increase every 2 weeks as tolerated.
• Maintenance: individualised to glycaemic targets up to the licensed maximum.

Patient counselling points include taking with food to reduce GI effects, being aware of hypoglycaemia triggers and carrying fast‑acting carbohydrate.

Interactions Overview (Food, Drink, Drugs, Mhra Yellow Card Data)

Patients often want to know which foods, drinks or medicines interact with their combination tablet.

Alcohol increases the risk of lactic acidosis with metformin and can worsen glycaemic control, so advise patients to limit intake and be cautious.

Concurrent hypoglycaemic agents such as insulin or meglitinides increase the risk of hypoglycaemia when combined with glyburide.

Glyburide is metabolised in part by CYP pathways, so strong CYP2C9 modulators may alter glyburide levels and require careful review.

Iodinated contrast media and other nephrotoxins that impair renal function raise metformin‑associated risks and are a common trigger for temporary suspension.

Yellow Card reports to date predominantly flag hypoglycaemia and gastrointestinal events rather than novel interactions, but clinicians should check current MHRA trends for emerging signals.

Pharmacies should use medication reconciliation checklists and NHS electronic prescribing alerts to flag contraindicated eGFR and interacting drugs.

Cultural Perceptions & Patient Habits (UK Patient Forums & Health Behaviour)

Patients ask what others like them say online and how attitudes affect medication choice.

UK forums and NHS feedback panels show pragmatic views: many patients appreciate single‑tablet combinations for convenience and improved adherence.

Concerns about hypoglycaemia and a preference for newer agents perceived as safer are common themes on sites such as Patient.info and other community panels.

Pharmacist counselling in high‑street chains and independent pharmacies is highly trusted and often used by patients for immediate reassurance before contacting their GP.

Digital behaviours such as the NHS App, online repeat prescriptions and teleconsultations increasingly shape adherence and side‑effect reporting.

Regional and socioeconomic differences affect uptake; prescription charge exemptions in Scotland, Wales and Northern Ireland versus England influence whether patients request branded generics or cost‑saving options.

• Top Patient Concerns: hypoglycaemia risk, gastrointestinal side effects, dosing complexity, interactions with alcohol, and long‑term safety.
• Top Pharmacist Counselling Prompts: check eGFR, discuss hypoglycaemia plan, advise on missed doses and travel/fasting.

Availability & Pricing Patterns (Boots, LloydsPharmacy, Nhs Pricing Differences)

People searching for where to buy often want a quick line on availability and cost.

Generics dominate UK supplies and are stocked by national chains such as Boots and LloydsPharmacy as well as NHS‑affiliated online pharmacies.

Packaging usually comes in blister packs of 30 or 60 tablets from multiple manufacturers, with dispensing driven by local formulary choices.

Pricing in England is affected by the NHS prescription charge; many patients pay a flat fee unless exempt, while Scotland, Wales and Northern Ireland have broader free prescribing for eligible groups.

Private prescriptions and online purchases can show price variation depending on supplier and pack size; hospital trusts may prefer alternatives based on cost‑effectiveness and safety.

In our online pharmacy, metformin + glyburide is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Prescribing Preferences (Nhs Alternatives)

Clinicians and patients ask which alternatives the NHS prefers when hypoglycaemia risk or comorbidity is a concern.

Common alternatives include metformin plus gliclazide, metformin plus a DPP‑4 inhibitor, or metformin plus an SGLT2 inhibitor when cardiovascular or renal benefit is sought.

Gliclazide is often chosen in NHS practice as a sulfonylurea with a lower reported hypoglycaemia risk compared with glyburide in some cohorts.

SGLT2 inhibitors have stronger evidence for cardiovascular and renal outcomes but can carry higher cost and genitourinary side effects.

Choice is influenced by age, comorbidity, hypoglycaemia risk and local formulary preferences, with many CCGs and trusts favouring cost‑effective generics where appropriate.

Patient preference factors include hypoglycaemia worry, pill burden and frequency of monitoring.

FAQ Section

Q1: Will I Get Hypoglycaemia On Metformin + Glyburide?

A: Glyburide can cause hypoglycaemia, especially with missed meals, alcohol or in older adults; carry fast‑acting carbohydrates and discuss dose review with your GP or pharmacist.

Q2: Can I Take This If I Have Reduced Kidney Function?

A: The combination is contraindicated if eGFR <30 ml/min; for eGFR 30–45 ml/min seek specialist advice because metformin carries a lactic acidosis risk.

Q3: What If I Miss A Dose?

A: Take it as soon as you remember unless it is nearly time for your next dose and do not double up.

Q4: Can I Buy It Over The Counter Or Online?

A: It is prescription only globally, so obtain it via NHS electronic prescription services or legitimate pharmacy chains; verify suppliers when buying online.

• Emergency Hypoglycaemia Actions: Give 15–20g fast‑acting carbohydrate (glucose gel, sugary drink); recheck in 10–15 minutes; seek urgent medical care if unconscious.
• Monitoring Schedule: baseline eGFR, HbA1c at initiation and per NHS review intervals, annual renal and liver checks unless more frequent review needed.

Storage note: store at controlled room temperature (20–25°C) in the original packaging.

Guidelines For Proper Use (UK Pharmacist Counselling & Nhs Support)

Patients value a clear checklist from the pharmacist when starting combination therapy.

Counselling should confirm indication, review recent eGFR and LFTs, check for interacting medicines and explain dosing—take with food to reduce gastrointestinal effects.

Warn patients about hypoglycaemia signs and when to seek urgent help, advise on missed doses and provide written leaflets or electronic resources through the NHS App.

Signpost patients to NHS 111, local diabetes education programmes and the Summary Care Record for coordinated care.

Record counselling in the patient record and ensure electronic prescriptions flag eGFR <30 ml/min and known allergies.

• Pharmacy Checklist: baseline tests, monitoring intervals (HbA1c and renal), hypoglycaemia action plan, travel/fasting advice, pregnancy counselling.
• Safety Reporting: encourage Yellow Card reporting for new adverse drug reactions.

Arrange a medication review at the annual diabetes review or sooner if the patient reports side effects or starts new interacting medicines.

Delivery Across United Kingdom